Corvus Pharmaceuticals, Inc.CRVSNASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank55
3Y CAGR+4.5%
5Y CAGR-5.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+4.5%/yr
vs -6.6%/yr prior
5Y CAGR
-5.0%/yr
Recent acceleration
Acceleration
+11.1pp
Accelerating
Percentile
P55
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$9.25M+13.3%
2024$8.16M+18.6%
2023$6.88M-15.0%
2022$8.10M-14.9%
2021$9.52M-20.2%
2020$11.93M+9.7%
2019$10.88M+2.3%
2018$10.64M+4.1%
2017$10.22M+34.1%
2016$7.62M-